Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study

Elias Jabbour; Ibrahim Aldoss; Shaun Fleming; Ashish Bajel; Paul Cannell; Monika Bruggemann; Gerhard Zugmaier; Joan Morris; Yuqi Chen; Sonny Powar; Hansen Wong; Bjorn Steffen; Hagop Kantarjian; Nicola Goekbuget

Conference Proceedings

Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study

Elias Jabbour, Ibrahim Aldoss, Shaun Fleming, Ashish Bajel, Paul Cannell, Monika Bruggemann, Gerhard Zugmaier, Joan Morris, Yuqi Chen, Sonny Powar, Hansen Wong, Bjorn Steffen, Hagop Kantarjian, Nicola Goekbuget

BLOOD | ELSEVIER | Published : 2022

DOI: 10.1182/blood-2022-156080

University of Melbourne Researchers

Citation metrics

Keywords